Long-term ticagrelor with aspirin reduces thrombotic events in patients with prior MI and no stenting

  • Furtado RHM & al.
  • Eur Heart J
  • 7 Dec 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Long-term dual antiplatelet therapy (DAPT) with ticagrelor and aspirin decreased atherothrombotic risk in patients with prior myocardial infarction (MI) irrespective of previous coronary stenting.
  • Risk reduction was higher in patients without stenting compared to those with stenting.

Why this matters

  • Findings highlight the benefits of DAPT in the prevention of spontaneous atherothrombotic events and suggest that ticagrelor may be considered for long-term in high-risk patients with prior MI and no history of stenting.

Study design

  • The PEGASUS-TIMI 54 study of 21,090 patients with prior MI (1-3 years; 4199 without stenting and 16,891 with ≥1 stents) who were randomly assigned to receive ticagrelor (60 and 90 mg) or placebo twice daily in addition to aspirin.
  • Primary outcomes: major adverse cardiovascular events (MACEs; cardiovascular (CV) death, MI and stroke).
  • Exploratory net clinical outcome: composite of CV death, MI, stroke, fatal bleeding or intracranial haemorrhage.
  • Funding: AstraZeneca to Brigham and Women’s Hospital.

Key results

  • Within the placebo group, patients without stenting had a higher absolute risk for MACEs vs those with stenting (HR, 1.41; 95% CI, 1.15-1.73; P=.0008).
  • Risk reduction in MACE with ticagrelor was similar in patients without (HR, 0.82; 95% CI, 0.68-0.99) and with (HR, 0.85; 95% CI, 0.75-0.96; Pinteraction=.76) stenting.
  • Ticagrelor vs placebo group had a lower risk for CV death (HR, 0.80; 95% CI, 0.62-1.03; P=.087) and all-cause mortality (HR, 0.79; 95% CI, 0.64-0.99; P=.036) in patients without stenting.
  • The risk for major bleeding increased with ticagrelor in patients without (HR, 1.93; 95% CI, 0.99-3.78) and with (HR, 2.65; 95% CI, 1.90-3.68; Pinteraction=.41) stenting.

Limitations

  • Subgroup analysis was not powered for all MACE components and safety endpoints.